bendazole lab bpc 157 BPC-157 VIAL - High Purity Laboratory Research Peptide BPC-157 + TB-500 Research Blend

Select days of the week when alcohol is off the menu

With a clean setup, the right needle, a well-chosen injection site, and a slow, confident push of the plunger, home administration becomes routine

Quality & Compliance Every batch of BPC-157 / TB-500 Blend is produced to exacting laboratory standards

Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols

The supplier blend (Ion Peptides) comes in two ratios in a 3 mL maximum vial : a 10/3 vial (10 mg tesamorelin + 3 mg ipamorelin, 13 mg total) and a 5/5 vial (5 mg tesamorelin + 5 mg ipamorelin, 10 mg total)